In-Vitro Transcription Templates Global Market Report 2024

The in-vitro transcription templates market size has grown exponentially in recent years. It will grow from $0.82 billion in 2023 to $1.01 billion in 2024 at a compound annual growth rate (CAGR) of 23.4%. The growth observed during the historic period can be attributed to several factors, including a rise in chronic disease cases, increased investments in research and development within the healthcare and pharmaceutical sectors, advancements in gene therapy technologies, collaborative partnerships, and notable developments in the field of gene therapy.

The in-vitro transcription templates market size is expected to see exponential growth in the next few years. It will grow to $2.35 billion in 2028 at a compound annual growth rate (CAGR) of 23.5%. The anticipated growth in the forecast period can be linked to several factors, including advancements in biotechnology, a heightened focus on research and development activities, increased utilization of in-vitro transcription templates, growing demand for early disease diagnosis, and a rising need for mRNA-based vaccines. Major trends expected during this period include advancements in RNA synthesis technologies, technological innovations, progress in biotechnology, improvements in enzymatic synthesis techniques, and the integration of automation and digitalization in the field.

The rise in gene therapy's prominence is anticipated to drive growth in the in-vitro transcription templates market. Gene therapy involves modifying cellular genes to treat or prevent illnesses by rectifying defective genes. Technological advancements such as CRISPR, substantial investments, and recent treatment successes have heightened interest in this approach. In-vitro transcription templates play a crucial role in gene therapy by providing the necessary RNA molecules for mRNA-based therapies, siRNA-based therapies, and gene editing technologies, enabling the treatment of genetic disorders and diseases. For instance, as of March 2024, the Food and Drug Administration (FDA), a US-based federal agency under the Department of Health and Human Services, reported approving 36 gene therapies, with another 500 in the pipeline. They expect to approve 10-20 annually by 2025, further emphasizing the growing focus on gene therapy driving the in-vitro transcription templates market's expansion.

Key players in the in-vitro transcription templates market are actively developing self-amplifying RNA synthesis services to enhance RNA-based therapy efficiency and effectiveness, reduce production costs, and improve patient outcomes across various therapeutic applications. This technology allows RNA production capable of self-replication within host cells, leading to heightened protein expression from minimal RNA input, thereby improving RNA-based therapy efficiency and effectiveness. For example, in May 2024, GenScript Biotech Corporation, a US-based biotechnology firm, unveiled a self-amplifying RNA (saRNA) synthesis service, expanding its in-vitro transcription RNA synthesis offerings. This new service boosts the potency and efficacy of vaccines, immunotherapies, and gene therapies by enabling robust protein expression from small RNA quantities. The saRNA platform aims to decrease dosages, lower production costs, and enhance patient outcomes, supported by extensive research and development ensuring high purity and improved protein expression.

In September 2022, Lonza, a Switzerland-based pharmaceutical and biotechnology company, partnered with Torchlight to incorporate Touchlight's innovative doggybone DNA (dbDNA) technology into its mRNA development and manufacturing services. This collaboration broadens Lonza's customer offerings, providing faster, scalable, and purer alternatives to traditional plasmid DNA (pDNA) methods, strengthening Lonza's integrated mRNA manufacturing capabilities. Torchlight, a UK-based biotechnology firm, specializes in DNA production and development through an enzymatic process.

Major companies operating in the in-vitro transcription templates market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Eurofins Genomics LLC, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Integrated DNA Technologies Inc., Promega Corporation, Genescript Biotech Corporation, Takara Bio Inc., New England Biolabs, OriGene Technologies Inc., Cayman Chemical, Synthego Corporation, Synbio Technologies, Creative Diagnostics, VectorBuilder Inc., Bio-Synthesis Inc., TriLink BioTechnologies, Norgen Biotek Corporation, Genaxxon BioScience GmbH, Enzo Life Sciences Inc., GeneCopoeia.

North America was the largest region in the in-vitro transcription templates market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro transcription templates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the in-vitro transcription templates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

In-vitro transcription templates are specific DNA sequences crafted to guide RNA synthesis under controlled laboratory conditions. These templates feature designated promoter regions recognized by RNA polymerase, enabling the efficient production of RNA molecules for diverse applications such as research, diagnostic advancements, and therapeutic development. They serve as reliable and precise resources for RNA synthesis, supporting activities in molecular biology and genetic investigations.

The primary applications of in-vitro transcription templates are in vaccine development and therapeutic production. Integral multi-tandem valves represent a category of single-unit valves that consolidate multiple control functions into a compact body. These valves find utility across various research stages including exploratory and clinical phases in treating ailments such as cancer, infectious diseases, lifestyle disorders, genetic conditions, and other medical conditions. They are utilized by pharmaceutical and biotechnology firms, contract research organizations (CROs) and contract manufacturing organizations (CMOs), academic and research institutions, and other relevant entities.

The in-vitro transcription templates market research report is one of a series of new reports that provides in-vitro transcription templates market statistics, including the in-vitro transcription templates industry global market size, regional shares, competitors with in-vitro transcription templates market share, detailed in-vitro transcription templates market segments, market trends, and opportunities, and any further data you may need to thrive in the in-vitro transcription templates industry. These in-vitro transcription templates market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The in-vitro transcription templates market consists of revenues earned by entities by providing services such as RNA synthesis, quality control services, scale-up production, and technical support. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-vitro transcription templates market also includes sales of DNA plasmids, linearized DNA, and synthetic oligonucleotides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.